Shi Jia

CSPC Pharmaceutical Group, often referred to as Shiyao Group or Shijiazhuang Pharmaceutical, is a leading integrated pharmaceutical company in China. The company operates across the entire value chain, from research and development to the manufacturing and sale of active pharmaceutical ingredients (APIs) and finished drug products. CSPC is particularly well-known for its strong presence in therapeutic areas such as cardiovascular disease, oncology, neurology, and anti-infectives. In recent years, the company has aggressively expanded into innovative biologics and mRNA technology, notably launching China's first domestically developed mRNA COVID-19 vaccine. With a robust pipeline of over 300 programs, CSPC remains a dominant force in the Chinese healthcare market and a growing player in global drug development.